Archives

  • 2018-07
  • 2018-10
  • 2018-11
  • 2019-04
  • 2019-05
  • 2019-06
  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2019-12
  • 2020-01
  • 2020-02
  • 2020-03
  • 2020-04
  • 2020-05
  • 2020-06
  • 2020-07
  • 2020-08
  • 2020-09
  • 2020-10
  • 2020-11
  • 2020-12
  • 2021-01
  • 2021-02
  • 2021-03
  • 2021-04
  • 2021-05
  • 2021-06
  • 2021-07
  • 2021-08
  • 2021-09
  • 2021-10
  • 2021-11
  • 2021-12
  • 2022-01
  • 2022-02
  • 2022-03
  • 2022-04
  • 2022-05
  • 2022-06
  • 2022-07
  • 2022-08
  • 2022-09
  • 2022-10
  • 2022-11
  • 2022-12
  • 2023-01
  • 2023-02
  • 2023-03
  • 2023-04
  • 2023-05
  • 2023-06
  • 2023-07
  • 2023-08
  • 2023-09
  • 2023-10
  • 2023-11
  • 2023-12
  • 2024-01
  • 2024-02
  • 2024-03
  • 2024-04
  • Hypothalamic hamartoma HH is a rare about

    2018-11-14

    Hypothalamic hamartoma (HH) is a rare (about 1:100,000) developmental, non-neoplastic malformation involving the small hypothalamic area located between the infundibular stalk and the mammillary bodies (). HH can be associated with a range of neurological and/or endocrinogical manifestations (). However, HH typical clinical hallmarks are compulsive bursts of laughter of epileptic nature with no sense of mirth, called gelastic seizures, and first described by Trousseau in 1877 (). These attacks usually start during infancy or childhood and were demonstrated to originate directly from the HH (). Moreover, in most patients, other seizure types may occur in association with a severe encephalopathy that can eventually lead to intellectual disability within few years (). Antiseizure drugs are inexorably ineffective and cannot avoid the cognitive dysfunction whereas the catastrophic evolution can be interrupted up to completely reverted by HH surgical ablation (). Hence, this potentially reversible encephalopathy is an amazing in vivo model to investigate the process of human epileptogenesis and to find new therapeutic options in patients with drug-resistant epilepsy. The intrinsic epileptogenicity of HH is explained by the Concanamycin A cost peculiar anatomo-functional organization and, in particular, by the electrophysiological properties of small Concanamycin A cost gamma-aminobutyric (GABA)-ergic neurons that make this structure highly epileptogenic and refractory to antiseizure drugs, regardless their mechanism of action. Li and colleagues () previously demonstrated, by means of patch-clamp recordings, the functional rundown of GABA-A receptors in neurons from surgically resected HH tissue, in line with the view that a dysfunction of GABAergic transmission plays a crucial role in epileptogenesis in these patients. Nonetheless, it is unlikely that GABA rundowns are the only functional changes occurring in HH tissue. Gap junctions are cell-to-cell channel-forming structures formed by specialized proteins (connexins [Cx]) which allow direct electrical coupling and chemical communication between adjacent neurons in central nervous system (CNS) (). Cx36 is the main neuronal connexin, although others have been variably detected in mature neurons. In most CNS regions, including the cortex and hypothalamus, the incidence of neuronal gap-junctions physiologically increases during the first two postnatal weeks and then decrease by the end of the third–fourth week. Cx36 and gap-junctions expression are transiently stimulated following a wide range of neuronal injuries, such as ischemia, spinal cord injury, epilepsy and inflammation (). Gap junctions likely contribute to the pathogenesis of epilepsy, particularly with respect to enhancing synchronous GABA activity of neuronal subgroups within epileptic networks (). However, although the pharmacological blockade of gap junctions significantly reduces seizure occurrence (), the potential for gap-junction blockers for treatment of human epilepsy remains still largely unexplored. In this issue of , Wu and colleagues demonstrated that, in human HH, neuronal gap junctions between small GABAergic HH neurons participate in the genesis of epileptic-like discharges (). The authors studied surgically resected HH tissue obtained from 27 patients all affected by treatment-resistant epilepsy and a history of gelastic seizures. Intellectual disability or developmental retardation was present in 13 (48%) patients and prior history of central precocious puberty was present in nine (33%) subjects. Wu and colleagues showed that HH tissue displayed a marked up-regulation of Cx43 and Cx36 protein levels when compared to normal hypothalamic control tissue. The increase of both connexins may relate to immature properties of HH tissue and immunohistochemistry confirmed that Cx36 was mainly expressed within neuron clusters while Cx43 was detected outside of neuronal networks. Biocytin injection into single recorded small HH neurons showed labeling of adjacent neurons, which was not observed in the presence of the neuronal gap-junction blocker, mefloquine. Finally, microelectrode field recordings from freshly resected HH slices demonstrated spontaneous ictal/interictal-like discharges which were significantly reduced by the application of gap-junction blockers without alterations of the action-potential firing of small GABA neurons observed with patch-clamp whole-cell recordings.